Article History
Received: 12 November 2019
Revised: 22 June 2020
Accepted: 19 August 2020
First Online: 24 September 2020
Ethics approval and consent to participate
: Not applicable for this review article.
: Not applicable for this review article.
: H.W., L.K. and Y.B. declare no competing interests. K.P. has received honoraria from Agena, Illumina and Menarini, and is a member of the Editorial Board of the <i>British Journal of Cancer</i>.
: L.K. was financially supported by Fondation de France, KMU-innovativ-23 n°031B0843D and Roggenbuck Stiftung. Y.B. and K.P. were financially supported by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 765492, KP and HW have received support from Deutsche Forschungsgemeinschaft (DFG), Priority Program SPP2084 and were supported by CANCER-ID, IMI grant (n° 115749), from EU (FP7/2007-2013) and EFPIA companies in kind contribution, K.P. received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 834974).